BioSpace News Archive

Innovative Medicines Canada released the following statement today in response to the release of revised PMPRB pricing guidelines:

Mainstay Medical Holdings plc announced that the U.S. Food and Drug Administration has approved the Company’s Premarket Approval application for ReActiv8®, its implantable neurostimulation system to treat intractable chronic low back pain.

FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today announced favorable topline results from its Phase 1 randomized, double-blind, placebo-controlled study of ultramicronized palmitoylethanolamide (PEA), or FSD201. This single-site study was conducted at the Alf

Phase 1 portion of the Phase 1/2a trial, 48 healthy volunteers were treated with either single or multiple weekly dose regimens

G1 Therapeutics, Inc. and Genor Biopharma Co. Inc. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced it has resumed in-person patient visits for casting, fitting and delivering its MyoPro® powered braces in states that are now allowing such interactions.

Immunic, Inc. announced that the company is set to join the broad-market Russell 3000® Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective after the US market opens on June 29, according to a final list of additions accessed on June 19.

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor Curcumin shows increased anticancer activity when conjugated to proprietary peptide SORT1+ technology significantly widens therapeutic window of traditional cytotoxic cancer treatments

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced dosing of the first patient in a multicenter Phase 1 clinical trial evaluating the combination of RMC-4630 (SAR442720), the company’s investigational SHP2 inhibitor, and pembrolizumab (Keytruda ® ), an anti-PD-1 antibody. The trial, which is being sponsored and conducted

Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it will be presenting at Proactive One2One Virtual Investor Forum on June 23, 2020. Dr. Heman Chao, Chief Executive Officer of Helix is scheduled to present on Tuesday, June 23 rd at approximately 1:20pm Eastern Time. The presentation will be web